Share ownership Vanda Pharmaceuticals Inc.

VNDA

US9216591084

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 16:51:37 11/03/2026 GMT			5-day change	1st Jan Change
9.465 ^USD	-0.99%		+15.49%	+7.37%

03-05	Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target	MT
03-05	Vanda Pharmaceuticals Insider Sold Shares Worth $1,276,971, According to a Recent SEC Filing	MT

Share class: Vanda Pharmaceuticals Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	58,308,144	56,470,955 ( 96.85 %)	0	96.85 %

Major shareholders: Vanda Pharmaceuticals Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 11.88 %	7,023,642	11.88 %	63 M $
Vanguard Fiduciary Trust Co. 6.314 %	3,731,851	6.314 %	33 M $
Renaissance Technologies LLC 5.72 %	3,380,961	5.72 %	30 M $
Mihael Polymeropoulos 4.576 %	2,704,496	4.576 %	24 M $
Acadian Asset Management LLC 4.078 %	2,410,414	4.078 %	21 M $
DFA Australia Ltd. 3.506 %	2,072,372	3.506 %	18 M $
AIGH Capital Management LLC 3.381 %	1,998,431	3.381 %	18 M $
Millennium Management LLC 2.841 %	1,679,013	2.841 %	15 M $
Geode Capital Management LLC 2.355 %	1,391,790	2.355 %	12 M $
STATE STREET CORPORATION 2.138 %	1,263,539	2.138 %	11 M $
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	66.08%
Individuals	8.21%
Other	2.96%
State Street Corp.	2.14%
SEI Investments Co.	0.32%
Manulife Financial Corp.	0.03%
Governments	0.03%
Unknown	20.23%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	63.63%
Individuals	8.21%
Australia	3.51%
Canada	1.35%
United Kingdom	1.01%
Ireland	0.7%
Germany	0.68%
Monaco	0.33%
Norway	0.23%
Hong Kong	0.05%
France	0.03%
Spain	0.02%
China	0.02%

Based on 1000 largest holdings

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâ€™s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Employees

533

Sector

Biotechnology & Medical Research

More about the company